Tirzepatide and Hashimoto's disease: what the clinical evidence tells us

What the SURMOUNT trials tell us about thyroid conditions and tirzepatide

The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity or overweight and at least one weight-related condition to tirzepatide or placebo over 72 weeks. Participants with controlled hypothyroidism were not excluded, meaning some people with Hashimoto's disease were almost certainly included in the data. Average body-weight reductions of around 20–21% at the highest dose were observed. Those headline results say nothing specific about Hashimoto's as a subgroup, but they do confirm that stable hypothyroidism was not treated as a barrier to participation.

The UK prescribing information for tirzepatide, published on the electronic Medicines Compendium, lists the conditions that rule out use or require caution. Autoimmune hypothyroidism in the form of Hashimoto's is not among them. The caution that does apply to the thyroid concerns a personal or family history of medullary thyroid carcinoma or MEN2, which is a completely different condition from Hashimoto's. Conflating the two is one of the most common sources of confusion patients bring to a first consultation, and it is worth clearing up plainly: the thyroid carcinoma precaution in the prescribing information does not apply to Hashimoto's disease.

Taken together, the trial evidence and the licensed prescribing information both suggest tirzepatide can be considered in Hashimoto's, with appropriate clinical oversight, and our dedicated page covering Mounjaro and Hashimoto's disease goes into further detail for anyone who wants a deeper look at that specific combination. That oversight is the essential part.

How Hashimoto's disease can affect weight and what tirzepatide addresses

Hashimoto's thyroiditis drives weight gain through more than one route. When thyroid hormone levels fall, basal metabolic rate slows, appetite regulation can shift, and fatigue makes activity harder to maintain. For some people, weight gained during an undertreated or fluctuating phase of Hashimoto's persists even after thyroid replacement therapy brings TSH into range, because the underlying biology of adiposity does not reverse automatically once hormone levels normalise.

This is the gap tirzepatide targets. As a dual GIP and GLP-1 receptor agonist, it works on two gut-hormone pathways involved in appetite signalling and gastric emptying, reducing the drive to eat and slowing digestion enough to extend fullness. You can read a fuller account of how tirzepatide works as a medicine if that level of mechanism is useful. The point for people with Hashimoto's is that the medicine acts independently of thyroid hormone pathways; it does not treat the autoimmune condition itself, but it addresses the weight biology that thyroid replacement often cannot fully resolve on its own.

Stable thyroid function at baseline matters, though. A prescriber will want to know that your hypothyroidism is reasonably controlled before starting tirzepatide, partly because distinguishing GI side effects of tirzepatide from symptoms of fluctuating thyroid function is much easier when you have a clear baseline.

Levothyroxine and tirzepatide: the interaction worth knowing about

People with Hashimoto's who take levothyroxine replacement therapy should be aware of one practical interaction. Tirzepatide slows gastric emptying, and oral medicines that depend on consistent absorption timing can behave differently when gastric motility changes. The NHS tirzepatide patient information advises that oral contraceptives should be taken with care during the first four weeks of treatment and after each dose increase for the same reason. Levothyroxine carries its own well-established sensitivity to absorption: it should be taken on an empty stomach, ideally at least 30 minutes before food, and kept well away from calcium, iron and some antacids.

The practical recommendation from prescribers is to keep the same levothyroxine routine throughout tirzepatide treatment, and to have thyroid function tested more frequently than you otherwise might, particularly in the first six months. Significant weight loss by any means can reduce the levothyroxine dose needed, so if TSH drifts out of range during treatment, a dose adjustment with your GP is the likely solution. It is also worth exploring how tirzepatide interacts with hormone therapies more broadly if you are taking anything else alongside levothyroxine.

None of this makes tirzepatide unsuitable for Hashimoto's patients, and people who want to understand further how the medicine behaves in the context of other conditions may find our page on tirzepatide and multiple sclerosis a useful comparison of how clinical oversight works when another long-term condition is present alongside obesity. It makes monitoring important, which is exactly what clinical supervision is for.

Getting a prescription: what the assessment involves for someone with Hashimoto's

Tirzepatide is a prescription-only medicine in the UK. That is not a bureaucratic obstacle; it is the structure that makes the medicine safe. A prescriber looking at your case with Hashimoto's will consider your current thyroid function, whether your hypothyroidism is stable, your full medication list (including levothyroxine dose and timing), your BMI, and any other weight-related conditions. If tirzepatide is appropriate, treatment typically starts at 2.5mg to allow your system to adjust, and you can find a complete breakdown of the dose options and how they are structured on our tirzepatide dosing guide.

Cost is a reasonable question at this stage. You can find current private treatment pricing on the Mounjaro price page, which explains what a legitimate private prescription includes. At nume, a GPhC-registered prescriber personally reviews every consultation. The assessment is not automated; a real clinician reads your answers and medical history the same day. If you would like to know more about the clinical team behind that process, our clinical lead's profile is publicly available.

If you have Hashimoto's and are thinking about whether tirzepatide might suit your situation, the right next step is a clinical conversation rather than a general search. You can start your free consultation and a prescriber will take it from there.